Invivoscribe
Invivoscribe, Complete Genomics Partner to Develop, Commercialize Oncology Biomarker Tests
The companies will collaborate to develop biomarkers tests for minimal residual disease (MRDs) in research and clinical setting using the DNBSeq sequencer.
Invivoscribe Leukemia CDx Assay Nabs IVDR Approval
The PCR-based test detects internal tandem duplications and tyrosine kinase domain mutations D835 and I836 in the FLT3 gene in patients with acute myelogenous leukemia.
In Brief This Week: Abbott, Thermo Fisher Scientific, Danaher, Oncocyte, Biocartis, More
News items for the week of Feb. 20, 2023.
Invivoscribe, Kronos Bio Partner on Companion Diagnostic Test for Leukemia Drug
The companion diagnostic assay would identify mutations in the NPM1 gene, which Kronos Bio is targeting with its investigational drug entospletinib.
Invivoscribe Receives Supplemental Approval for AML Kit
The firm has received a supplemental approval that provides its customers with an option to purchase its IVD-labeled FLT3 mutation assay for in-house testing.
Nov 27, 2018